CN114209804A - Navel patch for treating chronic obstructive pulmonary disease - Google Patents
Navel patch for treating chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CN114209804A CN114209804A CN202111433095.2A CN202111433095A CN114209804A CN 114209804 A CN114209804 A CN 114209804A CN 202111433095 A CN202111433095 A CN 202111433095A CN 114209804 A CN114209804 A CN 114209804A
- Authority
- CN
- China
- Prior art keywords
- parts
- container
- raw materials
- woven fabric
- ginger
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 39
- 238000003756 stirring Methods 0.000 claims abstract description 39
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 38
- 241000234314 Zingiber Species 0.000 claims abstract description 33
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 33
- 235000008397 ginger Nutrition 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 30
- 239000011248 coating agent Substances 0.000 claims abstract description 26
- 238000000576 coating method Methods 0.000 claims abstract description 26
- 235000011837 pasties Nutrition 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 21
- 241000218176 Corydalis Species 0.000 claims abstract description 21
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 18
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 18
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 18
- 229940116229 borneol Drugs 0.000 claims abstract description 18
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 18
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 210000004072 lung Anatomy 0.000 claims description 29
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 18
- 210000000936 intestine Anatomy 0.000 claims description 18
- 235000006463 Brassica alba Nutrition 0.000 claims description 16
- 244000140786 Brassica hirta Species 0.000 claims description 16
- 235000011371 Brassica hirta Nutrition 0.000 claims description 16
- 241000701408 Euphorbia kansui Species 0.000 claims description 15
- 235000021419 vinegar Nutrition 0.000 claims description 15
- 239000000052 vinegar Substances 0.000 claims description 15
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 12
- 201000005917 gastric ulcer Diseases 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 206010011224 Cough Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 230000017531 blood circulation Effects 0.000 claims description 7
- 230000004087 circulation Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 210000001156 gastric mucosa Anatomy 0.000 claims description 6
- 208000026435 phlegm Diseases 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 206010051986 Pneumatosis Diseases 0.000 claims description 5
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 230000005176 gastrointestinal motility Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 230000035790 physiological processes and functions Effects 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000033001 locomotion Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 230000001148 spastic effect Effects 0.000 claims description 2
- 210000001113 umbilicus Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 abstract description 33
- 230000008901 benefit Effects 0.000 abstract description 5
- 210000002429 large intestine Anatomy 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 8
- 230000004199 lung function Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000019693 Lung disease Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 241001591005 Siga Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a navel paste for treating chronic obstructive pulmonary disease, which comprises the following components in parts by weight: 1-5 parts of borneol, 8-12 parts of bighead atractylodes rhizome, 3-7 parts of cinnamon, 2-8 parts of clove, 9-15 parts of corydalis tuber and 1-5 parts of ginger, and the preparation method comprises the following steps: the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container; step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min; step three: stopping stirring when the raw materials in the container are pasty; step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm; step five: the invention adopts the traditional Chinese medicine external treatment method, has the advantages of curative effect, less side effect, convenient use, less contraindication, wide use, difficult generation of dependence and good application prospect.
Description
Technical Field
The invention relates to a wide range, in particular to an umbilical paste for treating chronic obstructive pulmonary disease.
Background
In recent years, due to the increasing deterioration of ecological environment, the prevalence rate and morbidity of COPD in China are high for a long time, the conventional treatment scheme of Western medicine at present has poor expected effect, the fatality rate and disability rate cannot be reduced by long-term repeated treatment, and heavy economic burden is brought to society, families and individuals. Therefore, it is necessary to find an effective treatment method with less toxic and side effects.
Clinically, most patients with COPD are often associated with symptoms such as abdominal distension and borborygmus, loose stool or difficult defecation, poor appetite and the like in an acute exacerbation period, and asthma exacerbation and inappetence can occur if the symptoms are not solved in time. Actually, the clinical phenomenon has been described in ancient medical books, such as Ling Shu & four seasons Qi, which is marked by the symptoms of frequent twitching in the abdomen, upward rushing to the chest, failure to relieve the asthma and pathogenic factors in the large intestine, and the symptoms of Su Wen & Ke Lun: for the lung cough, it is accepted by the large intestine. The large intestine cough with its vector remains, clearly indicating the pathological influence of the lung and the large intestine on each other. The lung and the large intestine not only supplement each other but also influence each other, without the dispersing of lung qi, the large intestine is difficult to moisten; without the descending of lung qi, the large intestine is difficult to conduct; without the regulation of lung qi, the large intestine is difficult to dry, so the lung is the large intestine, the large intestine is the large organ of the lung, the large organ governs the interior and the large intestine governs the exterior and the large intestine are the exterior and the interior. The scholars in China stand on the method for treating the lung diseases simultaneously, and can nourish the lung and moisten the intestines simultaneously to achieve the purpose of treating both principal and secondary aspects of diseases; in addition, lung disease treatment of the intestine achieves the purpose of treating lung disease by using medicaments to regulate the functional state of the intestine. Therefore, the lung and intestine co-treatment theory is played actively and has great significance in clinic.
Modern medical research shows that the intestinal flora is related to the onset and treatment of various diseases, wherein chronic lung diseases exist. The balance of the intestinal microenvironment depends on the relative balance of the species and quantity of the intestinal flora, but age factors, dietary structure, antibiotic abuse and disease states all disturb the homeostasis of the intestinal flora, leading to dysbacteriosis. The intestinal mucosal system is an important place of immunity in the human body. The intestinal flora can not only play a role in regulating the immune function of the system to human bodies, but also play a role in generating immune active factors to the physiological function of the human bodies. Meanwhile, the intestinal flora can also regulate the secretion of chemical substances in the intestinal tract and act on the organism through a certain chemical signal path. Research shows that when pathogenic heat attacks lung and stomach and intestine, the function of intestinal mucosa secreting sIgA is interfered, the intestinal mucosa sIgA level is obviously reduced, and the secretion of TNF-alpha and IL-10 cytokines is inhibited, so that the intestinal mucosa immune function is reduced. sIgA is an important substance for mucosal immunity, and the regulation of intestinal flora microecology can reduce or increase the secretion of sIgA [9] by intestinal mucosa, thereby changing the immunity of the organism and regulating the function of the organism. Therefore, mucosal immunity may be a pathway for the lung to communicate with the intestine, and a network communication between the lung and the intestine may be formed through the pathway, and the theory that the lung is exterior and interior with the large intestine is reflected by the physiological and pathological characteristics in the disease process;
the research is based on simultaneous treatment of lung and intestine and treatment of lung and intestine, and combines the theory of viscera and meridians and the pathogenesis characteristics of lung distension, the traditional Chinese medicine navel paste is applied to the Shenque point according to the syndrome differentiation, the efficacy of the traditional Chinese medicine can penetrate through the skin to adjust the functions of viscera, and the intestinal microenvironment tends to be stable by promoting the circulation of qi and blood around the navel and dredging the meridians, so that the intestinal mucosa immune system is regulated and controlled, and the aim of treating lung diseases is fulfilled. The method can avoid adverse reaction of the medicine and ensure clinical curative effect. Research results prove that the traditional Chinese medicine navel paste has better curative effect on relieving symptoms and improving lung function of COPD patients in clinical application than that of simple western medicine treatment, particularly has obvious effect on improving digestive tract symptoms such as loose stool or difficult defecation and the like, which indicates that the aim of treating both lung and intestine can be achieved by improving the functional state of the stomach and intestine, and the fact that objective clinical indexes cannot be provided for the change of the intestinal microenvironment before and after treatment due to condition limitation is insufficient in the research conclusion, and the correctness of the traditional theory of 'the exterior and interior of the lung and the large intestine' is proved by deeply excavating the objective basis of the connection between the action mechanism of the intestinal microenvironment and the pathogenic mechanism of COPD through a modern scientific research method, and related research thereof is bound to be great trend.
Disclosure of Invention
The invention aims to provide an umbilical paste for treating chronic obstructive pulmonary disease, which solves the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
an umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 1-5 parts of borneol, 8-12 parts of bighead atractylodes rhizome, 3-7 parts of cinnamon, 2-8 parts of clove, 9-15 parts of corydalis tuber and 1-5 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
As a further scheme of the invention: the formula and the weight components are as follows: 2-4 parts of perillaseed, 1-6 parts of white mustard seed, 0.2-1.5 parts of vinegar euphorbia kansui and 0.5-2 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
As a still further scheme of the invention: the ginger has the traditional Chinese medicine effect of warming the middle-jiao to dispel cold and relieving pain; the borneol has a regulating effect on the absorption of other oral medicines in the digestive tract, and can contract smooth muscle and promote gastrointestinal motility when being matched with the bighead atractylodes rhizome; the cinnamon aqueous extract can improve circulation and inhibit the formation of gastric ulcer by increasing the blood flow of gastric mucosa, and can eliminate the pneumatosis in the digestive tract and relieve the cramping pain of the stomach and the intestine by matching with clove; the alcohol extract and water extract of corydalis tuber can inhibit the growth of helicobacter pylori, the effect is possibly related to the action mechanism of corydalis tuber for resisting gastric ulcer, tetrahydropalmatine also has obvious effect of resisting experimental gastric ulcer, and the tetrahydropalmatine can increase the blood flow of gastric mucosa, improve circulation and inhibit the formation of gastric ulcer when used together with cinnamon.
As a still further scheme of the invention: the traditional Chinese medicine effects of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger are lung warming, phlegm reducing, cough relieving and asthma relieving, and the modern pharmacology has obvious functions of cough relieving, asthma relieving and phlegm eliminating, and can stimulate skin, increase the temperature of epidermis, enlarge gaps between cells on the surface, and promote the absorption of medicines.
Compared with the prior art, the invention has the beneficial effects that:
1. based on the simultaneous treatment of lung and intestine and the treatment of lung diseases and intestine, and the combination of the theory of viscera and meridians and the pathogenesis characteristics of lung distension, the Chinese medicinal navel paste is dialectically used for being pasted on the Shenque point, and the advantages of painlessness, non-wound property and simple and convenient operation are utilized to research the advantages, potential and social value of the application of the traditional Chinese medicine external treatment technology to the treatment of chronic diseases, so that patients can also psychologically and easily accept the intervention treatment of the traditional Chinese medicine;
2. the traditional Chinese medicine external treatment method has the advantages of curative effect, less side effect, convenient use, less contraindications, wide use, difficult generation of dependence and good application prospect.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Formulation I
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 1-5 parts of borneol, 8-12 parts of bighead atractylodes rhizome, 3-7 parts of cinnamon, 2-8 parts of clove, 9-15 parts of corydalis tuber and 1-5 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
The ginger has the effects of warming the middle-jiao, dispelling cold and relieving pain, the modern pharmacological action promotes gastrointestinal absorption, enhances the digestion function, eliminates the pneumatosis in the digestive tract, relieves the spastic pain of the gastrointestinal tract, has bidirectionality on the influence of the movement of the gastrointestinal tract, and can return the intestinal tract to the normal physiological state no matter the intestinal tract is in an excited or inhibited state;
the borneol has a regulating effect on the absorption of other oral medicines in the digestive tract, and can contract smooth muscle and promote gastrointestinal motility when being matched with the bighead atractylodes rhizome;
the cinnamon aqueous extract can improve circulation and inhibit the formation of gastric ulcer by increasing the blood flow of gastric mucosa, and can eliminate the pneumatosis in the digestive tract and relieve the cramping pain of the stomach and the intestine by matching with clove; the above-mentioned
The alcohol extract and water extract of corydalis tuber can inhibit the growth of helicobacter pylori, the effect is possibly related to the action mechanism of corydalis tuber for resisting gastric ulcer, tetrahydropalmatine also has obvious effect of resisting experimental gastric ulcer, and can increase the blood flow of gastric mucosa, improve circulation and inhibit the formation of gastric ulcer when used together with cinnamon;
formulation II
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 2-4 parts of perillaseed, 1-6 parts of white mustard seed, 0.2-1.5 parts of vinegar euphorbia kansui and 0.5-2 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
The traditional Chinese medicine effects of the perillaseed, the white mustard seed, the vinegar euphorbia kansui and the ginger are lung warming, phlegm reducing, cough relieving and asthma relieving, the modern pharmacology has obvious effects of cough relieving, asthma relieving and phlegm eliminating, the skin can be stimulated, the epidermis temperature is increased, gaps among cells on the surface are enlarged, the medicine absorption is promoted, and the promotion effect of transdermal absorption can also play the effects of promoting blood circulation to remove blood stasis, and relieving swelling and pain.
Example one
Formulation I
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 1 part of borneol, 8 parts of bighead atractylodes rhizome, 3 parts of cinnamon, 2 parts of clove, 9 parts of corydalis tuber and 1 part of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
Formulation II
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 2 parts of perillaseed, 1 part of white mustard seed, 0.2 part of vinegar euphorbia kansui and 0.5 part of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
Example two
Formulation I
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 2 parts of borneol, 10 parts of bighead atractylodes rhizome, 5 parts of cinnamon, 6 parts of clove, 10 parts of corydalis tuber and 2 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 20 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 2 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
Formulation II
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 3 parts of perillaseed, 4 parts of white mustard seed, 0.5 part of vinegar euphorbia kansui and 1 part of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 20 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 2 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
EXAMPLE III
Formulation I
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 5 parts of borneol, 12 parts of bighead atractylodes rhizome, 7 parts of cinnamon, 8 parts of clove, 15 parts of corydalis tuber and 5 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
Formulation II
An umbilical paste for treating chronic obstructive pulmonary disease comprises the following components by weight: 4 parts of perillaseed, 6 parts of white mustard seed, 1.5 parts of vinegar euphorbia kansui and 2 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
Clinical experiments
And (I) lung function index change conditions before and after intervention, and clinical effects are analyzed.
190 chronic obstructive pulmonary disease patients admitted in 2018 to 2019 in 10 months in the hospital are selected as research objects and are randomly divided into two groups, 95 patients in each group meet the inclusion standard, and the patients and family members thereof are approved. Wherein the observation group comprises 47 female patients, 48 male patients, the age is between 35 and 90 years, the average age is (45.21 +/-3.25) years, the control group comprises 39 female patients, 56 male patients, the age is between 41 and 90 years, the average age is (46.69 +/-5.23) years, the difference between the two groups of baseline data is not significant, P is more than 0.05, and the clinical comparability is achieved. Inclusion criteria were: (1) age and sex are not limited. (2) Drug experimenters did not participate in other drug trials within three months. (3) And signing the consent form under the premise of informed notice. Exclusion criteria were as follows: (1) decreased lung function; (2) patients with heart, brain, liver, kidney, etc.; (3) those who have developed lung function treatments; (4) the Chinese medicinal navel patch has anaphylaxis. The shedding criteria are as follows: patients who affect safety if the subject cannot strictly follow relevant regulations during the course of treatment; patients who have special conditions and other adverse reactions during the implementation of the treatment; the observer who is no longer involved in the clinical treatment is actively withdrawn. The patients in the control group are treated by western medicine conventional treatment, and the patients with chronic obstructive pulmonary disease in the observation group are treated by applying the traditional Chinese medicine navel paste method on the basis of adopting conventional western medicines for treatment. The medicine comprises borneol, perillaseed, cinnamon, clove, ginger, white mustard seed, white atractylodes rhizome, kansui root, corydalis tuber and the like. The using method comprises the following steps: times/d, 4 h/time. In this manner, use was continued for three weeks.
The lung function improvement was compared in two groups of patients. The lung function evaluation index comprises first second breathing gas volume (FEV1) and forced breathing vital capacity (FVC); average hospital stay and average number of rehospitalizations.
Data entry into Excel, analysis using SPSS19.0, with "n,%" representing the count data and checked by x 2; the measured data are expressed as "+/-s" and pass t test, P is less than 0.05, and the statistical value is represented. Lung function improvement was not significantly different (P > 0.05) from FEV1 and FVC prior to treatment intervention, both groups of FEV1 and FVC were elevated after treatment intervention, and the observed groups of FEV1 and FVC were more elevated (P <0.05), as shown in table 1:
table 1: comparison of FEV1, FVC improvement between groups (%,
)
compared with a control group, the traditional Chinese medicine navel paste can improve the lung function more obviously through the research, and has clinical significance.
And (II) evaluating the lung distension according to the lung distension curative effect standard of the Chinese medicine disease diagnosis curative effect standard after intervention. And (3) curing: symptoms disappear, and the mood is normal; improvement: the symptoms are reduced, and the mood is basically stable; and (4) invalidation: the symptoms and mood are not improved.
The selection conditions are the same as above. The treatment effect of the two groups of patients was compared with the length of hospitalization and the number of rehospitalizations. The 'standard of curative effect for diagnosing traditional Chinese medicine symptoms' is taken as the evaluation basis of the clinical treatment effect of patients with chronic obstructive pulmonary diseases. The evaluation grade can be divided into cure, improvement and ineffectiveness, wherein cure mainly means that the clinical symptoms and emotional states of patients meet normal standards after receiving corresponding treatment; the improvement mainly means that the clinical symptoms and emotional states of the patient are relieved or in a stable state after the patient receives corresponding treatment; the ineffectiveness mainly means that the clinical symptoms and emotional states of patients are not improved or even aggravated after the patients receive corresponding treatment.
Data entry into Excel, analysis using SPSS19.0, with "n,%" representing the count data and checked by x 2; the measured data are expressed as "+/-s" and pass t test, P is less than 0.05, and the statistical value is represented.
Comparison of the two groups of therapeutic effects
61/30 cases are respectively treated and improved in the observation group, the total effective rate of treatment is 95.79%, the total effective rate of treatment in the control group (83.16%) is remarkably low, and the statistical significance of difference (P is less than 0.05) is shown in Table 2:
table 2: comparison of the differences between groups (n,%) in the total efficacy of treatment
Compared with a control group, the navel patch has remarkable clinical curative effect and clinical significance in the study.
(III) comparison of hospital frequency and duration
The number of hospitalizations and the duration of hospitalization were significantly less or shorter in the observed group compared to the control group (P <0.05), as shown in Table 3.
Table 3: comparison of differences between hospital counts and time of hospitalization
| Group of | Number of cases | Number of hospitalization (times) | Length of stay (sky) |
| Control group | 95 | 2.12±1.45 | 15.05±6.48 |
| Observation group | 95 | 0.98±0.97 | 12.61±4.98 |
| t | / | 6.369 | 2.910 |
| P | / | ＜0.05 | ＜0.05 |
Compared with a control group, the study has the advantages that the hospitalization time and the hospitalization frequency are obviously reduced, and the clinical significance is realized.
(IV) before and after intervention, liver function, kidney function, blood routine, urine routine, stool routine and electrocardiogram examination are performed as safety indexes. 190 cases of chronic obstructive pulmonary disease patients admitted by the hospital are selected as study objects and randomly divided into two groups, and the study objects all meet the inclusion standard. The liver function, the kidney function, the blood routine, the urine routine and the electrocardiogram of all patients have no obvious change before and after treatment, and have no clinical significance, and simultaneously, the Chinese medicinal navel paste has no aggravation side effect and is relatively safe. The conventional method is limited by microorganism indexes, so that the sample amount is small (the patient does not want to take the sample), the sample amount is too small, the clinical significance is avoided, and the related research is continued in the future.
The research scheme is designed on the theory of treating both lung and intestine and lung and intestine by combining the pathogenesis characteristics of viscera, channels and collaterals and lung distension in the traditional Chinese medicine. According to the planned mission book, the research process is completed at present, and the study is popularized and used in other 6 hospitals and is confirmed by patients. The influence factors were obtained from the "leading edge of medicine".
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes in the embodiments and/or modifications of the invention can be made, and equivalents and modifications of some features of the invention can be made without departing from the spirit and scope of the invention.
Claims (4)
1. An umbilical paste for treating chronic obstructive pulmonary disease, which is characterized in that: the formula and the weight components are as follows: 1-5 parts of borneol, 8-12 parts of bighead atractylodes rhizome, 3-7 parts of cinnamon, 2-8 parts of clove, 9-15 parts of corydalis tuber and 1-5 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of borneol, largehead atractylodes rhizome, cinnamon, clove, corydalis tuber and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
2. The umbilicus patch for treating chronic obstructive pulmonary disease according to claim 1, characterized in that: the formula and the weight components are as follows: 2-4 parts of perillaseed, 1-6 parts of white mustard seed, 0.2-1.5 parts of vinegar euphorbia kansui and 0.5-2 parts of ginger, and the preparation method comprises the following steps:
the method comprises the following steps: putting a certain amount of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger into a container;
step two: crushing and stirring the raw materials in the container by using stirring and crushing equipment for 10-30 min;
step three: stopping stirring when the raw materials in the container are pasty;
step four: uniformly coating the pasty raw materials in the step three on the surface of the medical non-woven fabric by taking the medical non-woven fabric with a certain length, wherein the coating thickness is 1-3 mm;
step five: cutting and packaging the coated medical non-woven fabric to realize the preparation of the navel paste.
3. The umbilicus patch for treating chronic obstructive pulmonary disease according to claim 1, characterized in that: the ginger has the effects of warming the middle-jiao, dispelling cold and relieving pain, the modern pharmacological action promotes gastrointestinal absorption, enhances the digestion function, eliminates the pneumatosis in the digestive tract, relieves the spastic pain of the gastrointestinal tract, has bidirectionality on the influence of the movement of the gastrointestinal tract, and can return the intestinal tract to the normal physiological state no matter the intestinal tract is in an excited or inhibited state; the borneol has a regulating effect on the absorption of other oral medicines in the digestive tract, and can contract smooth muscle and promote gastrointestinal motility when being matched with the bighead atractylodes rhizome; the cinnamon aqueous extract can improve circulation and inhibit the formation of gastric ulcer by increasing the blood flow of gastric mucosa, and can eliminate the pneumatosis in the digestive tract and relieve the cramping pain of the stomach and the intestine by matching with clove; the alcohol extract and water extract of corydalis tuber can inhibit the growth of helicobacter pylori, the effect is possibly related to the action mechanism of corydalis tuber for resisting gastric ulcer, tetrahydropalmatine also has obvious effect of resisting experimental gastric ulcer, and the tetrahydropalmatine can increase the blood flow of gastric mucosa, improve circulation and inhibit the formation of gastric ulcer when used together with cinnamon.
4. The umbilicus patch for treating chronic obstructive pulmonary disease according to claim 2, characterized in that: the traditional Chinese medicine effects of perillaseed, white mustard seed, vinegar euphorbia kansui and ginger are lung warming, phlegm reducing, cough relieving and asthma relieving, and the modern pharmacology has obvious functions of cough relieving, asthma relieving and phlegm eliminating, and can stimulate skin, increase the temperature of epidermis, enlarge gaps between cells on the surface, and promote the absorption of medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111433095.2A CN114209804A (en) | 2021-11-29 | 2021-11-29 | Navel patch for treating chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111433095.2A CN114209804A (en) | 2021-11-29 | 2021-11-29 | Navel patch for treating chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114209804A true CN114209804A (en) | 2022-03-22 |
Family
ID=80698775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111433095.2A Pending CN114209804A (en) | 2021-11-29 | 2021-11-29 | Navel patch for treating chronic obstructive pulmonary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114209804A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557416A (en) * | 2004-02-03 | 2004-12-29 | 上海和黄药业有限公司 | Medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN102049033A (en) * | 2010-12-11 | 2011-05-11 | 张学顺 | Medicament for intervention treatment of chronic obstructive pulmonary disease and preparation method thereof |
| CN104906207A (en) * | 2015-07-02 | 2015-09-16 | 昆明市中医医院 | External treatment drug for preventing chronic obstructive pulmonary disease from attacking and preparation method of external treatment drug |
-
2021
- 2021-11-29 CN CN202111433095.2A patent/CN114209804A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557416A (en) * | 2004-02-03 | 2004-12-29 | 上海和黄药业有限公司 | Medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN102049033A (en) * | 2010-12-11 | 2011-05-11 | 张学顺 | Medicament for intervention treatment of chronic obstructive pulmonary disease and preparation method thereof |
| CN104906207A (en) * | 2015-07-02 | 2015-09-16 | 昆明市中医医院 | External treatment drug for preventing chronic obstructive pulmonary disease from attacking and preparation method of external treatment drug |
Non-Patent Citations (2)
| Title |
|---|
| 王力生，等: "中药脐贴治疗慢性阻塞性肺疾病的临床效果分析", 《医药前沿》 * |
| 黄新凤: "药物敷贴为主治疗慢性喘息型支气管炎84例", 《广西中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112220857A (en) | Traditional Chinese medicine powder for treating chronic gastritis by applying and preparation method thereof | |
| CN103800800B (en) | A kind of medicine for adult respiratory distress syndrome nursing and preparation method | |
| CN102085337A (en) | Patch for treating bronchial asthma of children | |
| CN102764406B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and preparation method thereof | |
| CN109464634A (en) | A kind of tonifying lung disperse accumulation particle and its preparation method and application | |
| CN102670803A (en) | External used Chinese plaster applied onto navel for curing infantile diarrhea | |
| CN111437375A (en) | Medicine for treating asthma | |
| CN100589834C (en) | Therapeutic agent for respiration diseases | |
| CN114209804A (en) | Navel patch for treating chronic obstructive pulmonary disease | |
| CN113768978B (en) | Yi medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN104958727B (en) | A kind of Chinese medicine composition for treating the childhood asthma paracmasis and its application | |
| CN104706690A (en) | Ching's briggsia extract and application thereof in medicament for treating gastric ulcer | |
| CN105998558B (en) | A kind of Chinese medicine composition and preparation method thereof for treating primary biliary cirrhosis | |
| CN111228367B (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN109091570B (en) | Traditional Chinese medicine for treating scleroderma | |
| CN103721180B (en) | A kind of Chinese medicine preparation for the treatment of cancerous protuberance | |
| CN115554374B (en) | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof | |
| CN104189314B (en) | It is a kind of to treat the turbid pharmaceutical composition for checking card high fat of blood of phlegm | |
| CN104055975B (en) | A kind of antitumor Chinese medicine preparation | |
| CN108553585A (en) | It is a kind of to treat lipoma and fibromatous Chinese medicine preparation and preparation method thereof | |
| CN108310218A (en) | A kind of Chinese medicine composition for treating ulcerative colitis and preparation method thereof and purposes | |
| CN111569003B (en) | Traditional Chinese medicine composition for treating cough variant asthma and extract and application thereof | |
| CN115444885B (en) | Traditional Chinese medicine composition for treating spleen and stomach deficiency-cold syndrome after gastric cancer operation and application thereof | |
| CN114588209B (en) | Citrus reticulata Blanco extract and its application in preparing medicine for treating salivary gland diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220322 |
|
| RJ01 | Rejection of invention patent application after publication |